Euroapi SAS
PAR:EAPI
Euroapi SAS
Capital Expenditures
Euroapi SAS
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Euroapi SAS
PAR:EAPI
|
Capital Expenditures
-€108m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Capital Expenditures
-€328.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-16%
|
|
|
Vetoquinol SA
PAR:VETO
|
Capital Expenditures
-€22m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Virbac SA
PAR:VIRP
|
Capital Expenditures
-€106.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
|
Medincell SA
PAR:MEDCL
|
Capital Expenditures
-€2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Euroapi SAS
Glance View
EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,342 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
See Also
What is Euroapi SAS's Capital Expenditures?
Capital Expenditures
-108m
EUR
Based on the financial report for Dec 31, 2024, Euroapi SAS's Capital Expenditures amounts to -108m EUR.
What is Euroapi SAS's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-6%
Over the last year, the Capital Expenditures growth was 19%. The average annual Capital Expenditures growth rates for Euroapi SAS have been -7% over the past three years , -6% over the past five years .
